Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Strides Pharma Science will engage with analysts and institutional investors in a Non-Deal Road Show hosted by DAM Capital on June 12, 2026. The meeting will be in-person in Mumbai.
Jun 08 2026 20:15:52
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Strides Pharma Science will conduct non-deal investor roadshows in New York, Chicago, Salt Lake City, and Los Angeles from June 2-5, 2026. These one-on-one meetings will utilize the Q4 FY26 earnings presentation as the discussion document for institutional investors.
May 28 2026 20:11:00
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Strides Pharma Science is scheduled to participate in a Non-Deal Road Show in the USA from June 2 to June 5, 2026. The company will conduct in-person one-on-one meetings with analysts and institutional investors across four cities: New York, Chicago, Salt Lake City, and Los Angeles. The discussions will include the Q4 FY26 earnings presentation.
May 28 2026 20:07:31
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Strides Pharma Science is scheduled to participate in a Non-Deal Road Show in the USA from June 2 to June 5, 2026. The company will conduct in-person one-on-one meetings with analysts and institutional investors across four cities: New York, Chicago, Salt Lake City, and Los Angeles. The discussions will include the Q4 FY26 earnings presentation.
May 28 2026 20:05:01
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Strides Pharma Science is scheduled to participate in a Non-Deal Road Show in the USA from June 2 to June 5, 2026. The company will conduct in-person one-on-one meetings with analysts and institutional investors across four cities: New York, Chicago, Salt Lake City, and Los Angeles. The discussions will include the Q4 FY26 earnings presentation.
May 28 2026 20:01:45
Strides Pharma Science Ltd - 532531 - Completion Of US-FDA Inspection At The Company'S Flagship Facility In Bangalore
Strides Pharma Science's flagship manufacturing facility in Bangalore underwent a US-FDA inspection, resulting in a Form 483 with five observations. The company will address these observations promptly to the FDA.
May 20 2026 22:02:30
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Directorate
Strides Pharma Science has elevated Mr. Venkata Seetharama Raju Pakalapati from COO to Executive Director for a 3-year term, effective June 1, 2026. Concurrently, Mr. Aditya Arun Kumar has been redesignated from Executive Director to Non-Executive Director.
May 20 2026 15:58:16
Strides Pharma Science Ltd - 532531 - Pronouncement Of Order By The Hon'Ble NCLT, Bengaluru Bench Regarding Scheme Of Arrangement For Demerger Of Demerged Undertaking Of Arco Lab Private Limited, A Wholly Owned Subsidiary Of Strides Pharma Science Limited.
Strides Pharma Science received NCLT approval for the scheme of arrangement to demerge Arco Lab's Life Sciences and Digital Innovation businesses into Pivot Path, effective April 10, 2025. This move aims to streamline its corporate structure.
May 20 2026 13:11:20
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Strides Pharma Science has published the audio recording of its earnings call, held today, May 18, 2026. This recording covers discussions on the audited financial results for Q4 and the full financial year ended March 31, 2026, and is accessible on the company's website.
May 18 2026 19:01:42
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Management
Strides Pharma Science appointed Venkata Seetharama Raju Pakalapati as Executive Director and Key Managerial Personnel (KMP) for a period of three years, effective June 1, 2026. He will oversee global technical operations and strategic management.
May 18 2026 16:50:44
Read More